{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"900","upperLimit":"2443","value":"1814.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Day 1: AUC0-12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1005","upperLimit":"3060","value":"2223.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Day 1: AUC0-24"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1141","upperLimit":"3536","value":"2413.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Day 1: AUC0-inf"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1788","upperLimit":"5725","value":"3797.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Day 23: AUC0-12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1936","upperLimit":"9948","value":"6103.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Day 23: AUC0-24"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1962","upperLimit":"20834","value":"10762.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Day 23: AUC0-inf"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"AUC0-12: Area under the concentration-time curve from time zero to 12 hours, AUC0-24: Area under the concentration-time curve from time zero to 24 hours, AUC0-inf: Area under the concentration-time curve from time zero to infinity","dispersionType":"Full Range","groups":[{"description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days.","id":"OG000","title":"MPM or NSCLC: BBI608 + Pem + CDDP (Phase 1 Part)"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic (PK) analysis population\n\n1 participant with MPM of 4 participants in the pharmacokinetic analysis population completed BBI608 administration on Day 14 in Cycle 1 and therefore was not included in the analysis for Cmax and AUC on Day 23.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 and Day 23","title":"Phase 1 Part: Area Under the Concentration-time Curve","type":"PRIMARY","unitOfMeasure":"h*ng/mL"}